Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis

Br J Haematol. 2015 Apr;169(1):77-80. doi: 10.1111/bjh.13262. Epub 2014 Dec 15.

Abstract

Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment-emergent peripheral neuropathy (TE-PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE-PN onset was 32 weeks and duration 11 months. Improvement after drug dose reduction or discontinuation was documented in only two patients. TE-PN was significantly associated with treatment response (P = 0·02) and longer survival (P = 0·048) but significance was lost during multivariate analysis that included treatment duration. TE-PN did not correlate with initial or maximum momelotinib dose or previous treatment with JAK inhibitor or thalidomide.

Keywords: momelotinib; myelofibrosis; myeloproliferative; neuropathy.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Clinical Trial, Phase III

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Benzamides / administration & dosage
  • Benzamides / adverse effects*
  • Female
  • Humans
  • Janus Kinase 1 / antagonists & inhibitors
  • Janus Kinase 2 / antagonists & inhibitors
  • Male
  • Middle Aged
  • Peripheral Nervous System Diseases / chemically induced
  • Peripheral Nervous System Diseases / enzymology
  • Peripheral Nervous System Diseases / epidemiology*
  • Prevalence
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / enzymology
  • Primary Myelofibrosis / epidemiology*
  • Pyrimidines / administration & dosage
  • Pyrimidines / adverse effects*
  • Risk Factors

Substances

  • Benzamides
  • Pyrimidines
  • N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
  • JAK1 protein, human
  • JAK2 protein, human
  • Janus Kinase 1
  • Janus Kinase 2